Description:
This study will treat participants with newly diagnosed, low, intermediate and high risk
rhabdomyosarcoma (RMS) using multi-modality risk-adapted therapy with standard or intensified
dose chemotherapy, radiation and surgical resection. Intermediate and high risk participants
will receive an additional 12 weeks (4 cycles) of maintenance therapy with anti-angiogenic
chemotherapy.
PRIMARY OBJECTIVE:
- Estimate event-free survival for intermediate risk participants treated with
vincristine, dactinomycin and cyclophosphamide with the addition of maintenance
anti-angiogenic therapy.
SECONDARY OBJECTIVES:
- Estimate the false negative rate and incidence of additional positive lymph nodes in
participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.
- Maintain a high local control rate in participants treated with surgery and/or limited
volume proton and photon radiation without dose escalation.
- Define the incidence and type of failure in participants who receive risk-adapted local
therapy relative to the primary tumor volume.
- Establish the feasibility of delivering 4 cycles of maintenance anti-angiogenic
chemotherapy in intermediate and high risk patients following standard chemotherapy.
- Estimate the event free survival for high risk patients receiving interval dose
compressed therapy and maintenance anti-angiogenic therapy.
- Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2
toxicities) related to proton beam therapy.
Title
- Brief Title: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
- Official Title: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
Clinical Trial IDs
- ORG STUDY ID:
RMS13
- SECONDARY ID:
NCI-2013-00913
- NCT ID:
NCT01871766
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Vincristine | Oncovin® | High-Risk |
Dactinomycin | Actinomycin-D, Cosmegen® | High-Risk |
Cyclophosphamide | Cytoxan(R) | High-Risk |
Bevacizumab | rhuMab, VEGF, Avastin® | High-Risk |
Sorafenib | Nexavar® | High-Risk |
Myeloid Growth Factor | G-CSF, Filgrastim, Pegfilgrastim | High-Risk |
Irinotecan | Camptosar ® | High-Risk |
Ifosfamide | Ifex ® | High-Risk |
Etoposide | VP-16, Vepesid® | High-Risk |
Etoposide Phosphate | Etopophos® | High-Risk |
Doxorubicin | Adriamycin® | High-Risk |
Dexrazoxane | Zinecard | High-Risk |
^1^1C-methionine | Contrast Media | High-Risk |
Purpose
This study will treat participants with newly diagnosed, low, intermediate and high risk
rhabdomyosarcoma (RMS) using multi-modality risk-adapted therapy with standard or intensified
dose chemotherapy, radiation and surgical resection. Intermediate and high risk participants
will receive an additional 12 weeks (4 cycles) of maintenance therapy with anti-angiogenic
chemotherapy.
PRIMARY OBJECTIVE:
- Estimate event-free survival for intermediate risk participants treated with
vincristine, dactinomycin and cyclophosphamide with the addition of maintenance
anti-angiogenic therapy.
SECONDARY OBJECTIVES:
- Estimate the false negative rate and incidence of additional positive lymph nodes in
participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.
- Maintain a high local control rate in participants treated with surgery and/or limited
volume proton and photon radiation without dose escalation.
- Define the incidence and type of failure in participants who receive risk-adapted local
therapy relative to the primary tumor volume.
- Establish the feasibility of delivering 4 cycles of maintenance anti-angiogenic
chemotherapy in intermediate and high risk patients following standard chemotherapy.
- Estimate the event free survival for high risk patients receiving interval dose
compressed therapy and maintenance anti-angiogenic therapy.
- Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2
toxicities) related to proton beam therapy.
Detailed Description
Participants will be stratified based on both a pretreatment staging system and a
post-surgery surgico/pathologic clinical grouping system. Treatment for low-risk (subset 1)
participants will consist of chemotherapy and radiation. Low-risk (subset 2) and
intermediate-risk participants will receive chemotherapy and radiation and/or undergo surgery
to destroy/remove the tumor. Intermediate-risk participants will also receive 16 weeks of
maintenance chemotherapy. High-risk participants will receive chemotherapy and radiation
therapy. High-risk participants will also receive additional maintenance therapy with
anti-angiogenic chemotherapy.
Trial Arms
Name | Type | Description | Interventions |
---|
Low-Risk, Subset 1 | Experimental | Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.
Participants also receive ^1^1C-methionine as described in the intervention section. | - Vincristine
- Dactinomycin
- Cyclophosphamide
- Myeloid Growth Factor
- ^1^1C-methionine
|
Low-Risk, Subset 2 | Experimental | Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed.
Participants also receive ^1^1C-methionine as described in the intervention section. | - Vincristine
- Dactinomycin
- Cyclophosphamide
- Myeloid Growth Factor
- ^1^1C-methionine
|
Intermediate-Risk | Experimental | Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.
Participants also receive ^1^1C-methionine as described in the intervention section. | - Vincristine
- Dactinomycin
- Cyclophosphamide
- Bevacizumab
- Sorafenib
- Myeloid Growth Factor
- ^1^1C-methionine
|
High-Risk | Experimental | Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy [vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed.
Participants also receive ^1^1C-methionine as described in the intervention section. | - Vincristine
- Dactinomycin
- Cyclophosphamide
- Bevacizumab
- Sorafenib
- Myeloid Growth Factor
- Irinotecan
- Ifosfamide
- Etoposide
- Etoposide Phosphate
- Doxorubicin
- Dexrazoxane
- ^1^1C-methionine
|
Eligibility Criteria
Inclusion Criteria:
- Newly diagnosed participants with localized rhabdomyosarcoma (RMS).
- Must have either low-, intermediate-, or high-risk disease, defined as:
- Low-risk: Embryonal, botryoid, spindle cell tumors only (Subset 1: Stage 1, Group
I; Stage 1 Group I; Stage 1 Group III orbital only; Stage 2 Group I; Stage 2
Group II) (Subset 2: Stage 1 Group III non orbit; Stage 3 Group I, II)
- Intermediate-risk: Embryonal, botryoid, or spindle cell RMS Stage 2 or 3 and
Group III; Alveolar, undifferentiated, or anaplastic RMS: Stage 1-3, group I-I;
I)
- High-risk: Embryonal, botryoid, spindle cell, alveolar, undifferentiated, or
anaplastic RMS with metastatic disease at diagnosis (stage 4).
- Participants treated on this protocol in the low or intermediate risk arm who
experience disease progression prior to week 13 will transfer to the high risk
arm and proceed with high risk chemotherapy starting at week 1 of the protocol.
- Age < 22 years (eligible until 22nd birthday)
- Performance level corresponding to ECOG score of 0, 1, or 2. The Lansky performance
score should be used for participants < 16 years
- Participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma
(excluding steroids) unless an emergency situation requires local tumor treatment.
Prior biopsy, surgical resection and lymph node sampling is allowed.
- Initiation of chemotherapy is planned within 6 weeks (42 days) of the definitive
biopsy or surgical resection.
- Adequate bone marrow function defined as:
- Peripheral absolute neutrophil count (ANC) ≥ 750/μL
- Platelet count ≥ 75,000/μL (transfusion independent)
- Adequate liver function defined as total bilirubin ≤ 1.5 x upper limit of normal (ULN)
for age. Participants with biliary or hepatic primaries with bilirubin values greater
than 1.5 x ULN may be enrolled on study if all other eligibility criteria are met.
- Adequate renal function defined as:
- Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.732 or
- Serum creatinine based on age and gender
- Participants with urinary tract obstruction by tumor must meet the renal function
criteria listed above AND must have unimpeded urinary flow established via
decompression of the obstructed portion of the urinary tract.
- Patients requiring emergency radiation therapy are eligible for enrollment on this
study.
- Females of child-bearing potential cannot be pregnant or breast-feeding. Female
participants ≥ 10 years of age or post-menarchal must have a negative serum or urine
pregnancy test within 24 hours prior to beginning treatment. Female participants who
are breast feeding must agree to stop breast feeding.
- Sexually active patients of childbearing potential must be willing to use effective
contraception during therapy and for at least 1 month after treatment is completed.
- No evidence of active, uncontrolled infection.
- All participants and/or their parents or legal guardians must sign a written informed
consent.
Exclusion Criteria:
- Participants who fail to meet one or more of the inclusion criteria will be excluded.
Inclusion Criteria for Contrast-Enhanced Ultrasound (CEUS) Sub-Study:
- Newly diagnosis or suspected diagnosis of previously untreated participants with
rhabdomyosarcoma (RMS). NOTE: Patients with suspected diagnosis of RMS may enroll on
screening part of study but must have histologic diagnosis to enroll on treatment part
of study.
- Must have either intermediate-risk or high risk disease.
- 0-21 years of age.
Exclusion Criterial for CEUS Sub-Study:
- Undergoing upfront surgical resection of the primary tumor.
- History of allergy to Optison(TM) contrast agent or blood products.
Maximum Eligible Age: | 21 Years |
Minimum Eligible Age: | N/A |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Event-free survival (intermediate risk arm) |
Time Frame: | 2 years after last intermediate risk arm enrollment |
Safety Issue: | |
Description: | To estimate event-free survival for intermediate risk participants treated by vincristine-dactinomycin-cyclophosphamide (VAC) with the addition of maintenance anti-angiogenic therapy |
Secondary Outcome Measures
Measure: | Event-free survival (high risk arm) |
Time Frame: | 5 years after last high-risk arm enrollment |
Safety Issue: | |
Description: | To estimate event-free survival for high risk participants. |
Measure: | Rate of false negative and false positive the sentinel lymph node procedure (low and intermediate risk arms) |
Time Frame: | 2 years after last low or intermediate arm enrollment |
Safety Issue: | |
Description: | Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection. |
Measure: | Rate of false negative and false positive the sentinel lymph node procedure (high risk arm) |
Time Frame: | 5 years after last high risk arm enrollment |
Safety Issue: | |
Description: | Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection. |
Measure: | Local failure rate (low and intermediate risk arms) |
Time Frame: | 2 years after last low or intermediate risk arm enrollment |
Safety Issue: | |
Description: | Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation |
Measure: | Local failure rate (high risk arm) |
Time Frame: | 5 years after last high risk arm enrollment |
Safety Issue: | |
Description: | Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation |
Measure: | Patterns of failure (low and intermediate risk arms) |
Time Frame: | 2 years after last low or intermediate risk arm enrollment |
Safety Issue: | |
Description: | Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume |
Measure: | Patterns of failure (high risk arm) |
Time Frame: | 5 years after last high risk arm enrollment |
Safety Issue: | |
Description: | Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume |
Measure: | Number of patients that complete all cycles of maintenance chemotherapy (intermediate risk arm) |
Time Frame: | 2 years after last low or intermediate risk arm enrollment |
Safety Issue: | |
Description: | Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in intermediate risk patients following standard chemotherapy. |
Measure: | Number of patients that complete all cycles of maintenance chemotherapy (high risk arm) |
Time Frame: | 5 years after last high risk arm enrollment |
Safety Issue: | |
Description: | Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in high risk patients following standard chemotherapy. |
Measure: | Incidence of CTC grade 3 and higher toxicities related to proton bream therapy (low and intermediate and high risk arms) |
Time Frame: | 2 years after last enrollment |
Safety Issue: | |
Description: | Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2 toxicities) related to proton beam therapy. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | St. Jude Children's Research Hospital |
Trial Keywords
- Rhabdomyosarcoma
- Radiation therapy
- Proton beam
Last Updated
July 2, 2021